Hms Capital Management, LLC Abb Vie Inc. Transaction History

Hms Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 15, 2019	SELL	$62.98 - $75.72 $2,960 - $3,558	-47 Closed	0 $0
Q2 2019 Jul 12, 2019	BUY	$65.7 - $83.98 $3,087 - $3,947	47 New	47 $3,000
Q1 2019 Apr 24, 2019	SELL	$77.14 - $90.79 $123,424 - $145,264	-1,600 Closed	0 $0
Q4 2018 Jan 14, 2019	SELL	$77.85 - $96.01 $1.51 Million - $1.86 Million	-19,408 Reduced 92.38%	1,600 $147,000
Q3 2018 Nov 02, 2018	SELL	$88.91 - $98.84 $15,648 - $17,395	-176 Reduced 0.83%	21,008 $1.99 Million
Q2 2018 Aug 06, 2018	BUY	$89.78 - $106.23 $625,227 - $739,785	6,964 Added 48.97%	21,184 $1.96 Million
Q1 2018 May 08, 2018	SELL	$92.01 - $123.21 $873,542 - $1.17 Million	-9,494 Reduced 40.04%	14,220 $1.35 Million
Q4 2017 Feb 05, 2018	BUY	$89.56 - $98.21 $82,843 - $90,844	925 Added 4.06%	23,714 $2.29 Million
Q3 2017 Oct 25, 2017	BUY	$69.85 - $89.22 $40,443 - $51,658	579 Added 2.61%	22,789 $2.03 Million
Q2 2017 Aug 11, 2017	BUY	N/A	22,210	22,210 $1.61 Million

3,852

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Hms Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Hms Capital Management, LLC with notifications on news.